Agilon Health Inc (AGL) concluded trading on Thursday at a closing price of $4.61, with 3.15 million shares of worth about $14.53 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.43% during that period and on March 27, 2025 the price saw a gain of about 1.99%. Currently the company’s common shares owned by public are about 412.19M shares, out of which, 303.54M shares are available for trading.
Stock saw a price change of 12.44% in past 5 days and over the past one month there was a price change of 37.20%. Year-to-date (YTD), AGL shares are showing a performance of 142.63% which decreased to -3.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.50 but also hit the highest price of $7.73 during that period. The average intraday trading volume for Agilon Health Inc shares is 5.60 million. The stock is currently trading 16.86% above its 20-day simple moving average (SMA20), while that difference is up 26.93% for SMA50 and it goes to 18.48% higher than SMA200.
Agilon Health Inc (NYSE: AGL) currently have 412.19M outstanding shares and institutions hold larger chunk of about 71.65% of that.
The stock has a current market capitalization of $1.90B and its 3Y-monthly beta is at 0.43. It has posted earnings per share of -$0.63 in the same period. It has Quick Ratio of 1.27 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AGL, volatility over the week remained 6.03% while standing at 8.29% over the month.
Stock’s fiscal year EPS is expected to rise by 51.54% while it is estimated to increase by 38.86% in next year. EPS is likely to grow at an annualized rate of 51.97% for next 5-years, compared to annual growth of 3.29% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on January 10, 2025 offering a Neutral rating for the stock and assigned a target price range of between $1.75 and $2.25 to it. On December 16, 2024, Macquarie Initiated their recommendations, while on December 11, 2024, Bernstein Initiated their ratings for the stock with a price target of $2.50. Stock get a Mkt perform rating from JMP Securities on November 11, 2024.
